Marktanalyse - Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H2 2016

Global Markets Direct
12.2016
62 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vasomotor Symptoms of Menopause (Hot Flashes) — Pipeline Review, H2 2016, provides an overview of the Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline landscape.

Vasomotor symptoms of menopause include hot flashes or night sweats that result from sudden opening of the blood vessels close to the skin, usually due to hormonal fluctuations in menopause and perimenopause. These symptoms are caused due to some medications, estrogen withdrawal, thyroid disease, diabetes, hyperhidrosis, anxiety and panic disorders, obesity, hormonally active tumors, chronic infections and neurological disorders.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vasomotor Symptoms of Menopause (Hot Flashes) — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Vasomotor Symptoms of Menopause (Hot Flashes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 5, 2 and 2 respectively.

Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Vasomotor Symptoms of Menopause (Hot Flashes) Overview 7

Therapeutics Development 8

Pipeline Products for Vasomotor Symptoms of Menopause (Hot Flashes) - Overview 8

Vasomotor Symptoms of Menopause (Hot Flashes) - Therapeutics under Development by Companies 9

Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Vasomotor Symptoms of Menopause (Hot Flashes) - Products under Development by Companies 13

Vasomotor Symptoms of Menopause (Hot Flashes) - Companies Involved in Therapeutics Development 14

EndoCeutics Inc 14

MenoGeniX Inc 15

Mithra Pharmaceuticals SA 16

NeRRe Therapeutics Ltd 17

Ogeda SA 18

Pherin Pharmaceuticals Inc 19

Radius Health Inc 20

TherapeuticsMD Inc 21

Vasomotor Symptoms of Menopause (Hot Flashes) - Therapeutics Assessment 22

Assessment by Monotherapy Products 22

Assessment by Combination Products 23

Assessment by Target 24

Assessment by Mechanism of Action 26

Assessment by Route of Administration 28

Assessment by Molecule Type 30

Drug Profiles 32

(acolbifene hydrochloride + prasterone) - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

(estradiol acetate + progesterone) - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

ESN-364 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Estetrol - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

FP-101 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

HBN-2 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

MNGX-100 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

NT-814 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

PH-80HF - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Q-122 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

RAD-1901 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Vasomotor Symptoms of Menopause (Hot Flashes) - Dormant Projects 51

Vasomotor Symptoms of Menopause (Hot Flashes) - Discontinued Products 53

Vasomotor Symptoms of Menopause (Hot Flashes) - Product Development Milestones 54

Featured News & Press Releases 54

Dec 05, 2016: TherapeuticsMD Announces Positive Top-Line Results from Pivotal Phase 3 Replenish Trial in Postmenopausal Women with Moderate to Severe Vasomotor Symptoms (VMS) Treated with TX-001HR 54

Sep 14, 2016: Euroscreen SA: Completes Enrollment in Phase II trial of lead candidate ESN364 in Menopausal Hot Flashes 55

Jul 19, 2016: EUROSCREEN opens US-IND for ESN364 on three Phase II trials 56

Apr 01, 2016: Radius to provide an update on RAD1901 at the ENDO 2016 Annual Meeting 56

Oct 13, 2015: TherapeuticsMD Completes Enrollment in Phase 3 Clinical Trial of Bio-identical Oral Combination of Estradiol and Progesterone Product Candidate 56

Sep 23, 2015: Euroscreen launches Phase 2 clinical trial with ESN364 as the first and unique non-hormonal causal treatment for menopausal Hot Flashes 57

Jan 06, 2014: TherapeuticsMD Announces Milestone Achievement of 50th Site for Phase 3 Clinical Trial of TX 12-001HR to Treat Symptoms of Menopause and Provide Endometrial Protection 57

Oct 18, 2013: TherapeuticsMD Poster Wins First-Place Prize at the North American Menopause Society 2013 Annual Meeting 58

Jun 19, 2010: Radius Presents Positive Phase IIa Study Results Of RAD1901 In Reducing Menopausal Hot Flashes 58

Jun 08, 2008: Radius Presents Preclinical Study Of RAD1901 At The Endocrine Society 2007 Annual Meeting 59

Appendix 61

Methodology 61

Coverage 61

Secondary Research 61

Primary Research 61

Expert Panel Validation 61

Contact Us 61

Disclaimer 62





List of Tables

Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes), H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by EndoCeutics Inc, H2 2016 14

Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by MenoGeniX Inc, H2 2016 15

Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by Mithra Pharmaceuticals SA, H2 2016 16

Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by NeRRe Therapeutics Ltd, H2 2016 17

Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by Ogeda SA, H2 2016 18

Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by Pherin Pharmaceuticals Inc, H2 2016 19

Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by Radius Health Inc, H2 2016 20

Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by TherapeuticsMD Inc, H2 2016 21

Assessment by Monotherapy Products, H2 2016 22

Assessment by Combination Products, H2 2016 23

Number of Products by Stage and Target, H2 2016 25

Number of Products by Stage and Mechanism of Action, H2 2016 27

Number of Products by Stage and Route of Administration, H2 2016 29

Number of Products by Stage and Molecule Type, H2 2016 31

Vasomotor Symptoms of Menopause (Hot Flashes) - Dormant Projects, H2 2016 51

Vasomotor Symptoms of Menopause (Hot Flashes) - Dormant Projects (Contd..1), H2 2016 52

Vasomotor Symptoms of Menopause (Hot Flashes) - Discontinued Products, H2 2016 53





List of Figures

Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes), H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 11

Assessment by Monotherapy Products, H2 2016 22

Number of Products by Targets, H2 2016 24

Number of Products by Stage and Targets, H2 2016 24

Number of Products by Top 10 Mechanism of Actions, H2 2016 26

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 26

Number of Products by Routes of Administration, H2 2016 28

Number of Products by Stage and Routes of Administration, H2 2016 28

Number of Products by Molecule Types, H2 2016 30

Number of Products by Stage and Molecule Types, H2 2016 30

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus